טוען...
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provided new opportunities for understanding disease pathogenesis and potential new targets for therapeutic intervention. One such target is leucine-rich repeat kinase 2 (LRRK2), an enigmatic enzyme implicated in bo...
שמור ב:
| הוצא לאור ב: | Clin Pharmacol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5076802/ https://ncbi.nlm.nih.gov/pubmed/27799832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S102191 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|